Efficacy and safety of raltitrexed-based transcatheter arterial chemoembolization for intermediate and advanced hepatocellular carcinoma: A multicenter real-world study.
hepatocellular carcinoma
overall survival
propensity-score matched analysis
raltitrexed
transcatheter arterial chemoembolization
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
12
08
2021
received:
03
04
2021
accepted:
26
08
2021
pubmed:
8
9
2021
medline:
8
9
2021
entrez:
7
9
2021
Statut:
ppublish
Résumé
This study aimed to evaluate efficacy and safety of raltitrexed-based transcatheter arterial chemoembolization (TACE) for intermediate and advanced hepatocellular carcinoma (HCC) using real-world evidence. All eligible HCC cases were collected from multiple centers in Chongqing, China, from January 2013 to December 2018 and divided into the raltitrexed group (raltitrexed + lobaplatin + pirarubicin) and control group (lobaplatin + pirarubicin). Propensity score matching (PSM) with a 1:1 ratio was used to eliminate the imbalance of potential confounding factors between groups. The primary end-point was overall survival (OS) and the secondary end-points were progression-free survival (PFS) and disease control rate. The median follow-up period for patients in the raltitrexed and control groups was 8.7 and 5.9 months, respectively. After PSM, median OS was 10.0 months in the raltitrexed group and 7.0 months in the control group (p = 0.002). The 6-month, 1-year, and 2-year OS rates of the raltitrexed group were significantly higher than those of the control group (78.2% vs. 60.9%, p = 0.010; 43.5% vs. 22.8%, p = 0.030; and 17.4% vs. 2.2% p = 0.001, respectively). Multivariate analysis of these propensity score-matched HCC patients revealed treatment, age, tumor size, lipiodol accumulation, and the number of TACE cycles as independent predictors of OS (all p < 0.05). The disease control rate of the raltitrexed and control groups was 87.4% and 65.8%, respectively (p < 0.001). Raltitrexed-based TACE can prolong the OS of patients with intermediate and advanced HCC in a real-world clinical setting, and is safe and tolerable.
Types de publication
Journal Article
Langues
eng
Pagination
1153-1163Subventions
Organisme : National Natural Science Foundation of China
ID : 81871608
Informations de copyright
© 2021 The Japan Society of Hepatology.
Références
Feng R, Zong Y, Cao S, Xu R. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Canc Commun. 2019;39:22.
Zhu RX, Seto W, Lai C, Yuen M. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver. 2016;10:332-339.
Cheung TT, Kwok PC, Chan S, Cheung C-C, Lee A-S, Lee V, et al. Hong Kong consensus statements for the management of unresectable hepatocellular carcinoma. Liver Canc. 2018;7:40-54.
Chen LT, Martinelli E, Cheng AL, Pentheroudakis G, Qin S, Bhattacharyya GS, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO. Ann Oncol. 2020;31:334-51.
Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:1164-74.
Choi C, Choi GH, Kim TH, Tanaka M, Meng M, Seong J. Multimodality management for Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma. Liver Canc. 2014;3:405-16.
Lee S, Lin C, Hsu Y, Liu Y, Chuang M, Ou M. Comparison of the efficacy of two microsphere embolic agents for transcatheter arterial chemoembolization in hepatocellular carcinoma patients. Canc Res Treat. 2020;52:24-30.
Gao Y, Li Z, Hong Y, Li T, Hu X, Sun L, et al. Decellularized liver as a translucent ex vivo model for vascular embolization evaluation. Biomaterials. 2020;240:119855.
Zhao M, Xiang P, Jiang H. Transarterial chemoembolization (TACE) with platinum versus anthracyclines for hepatocellular carcinoma: a meta-analysis. Int J Surg. 2018;53:151-8.
Feng F, Jiang Q, Jia H, Sun H, Chai Y, Li X, et al. Which is the best combination of TACE and sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis. Pharmacol Res. 2018;135:89-101.
Chen M, Wu L, Tu J, Zhao Z, Fan X, Mao J, et al. miR-590-5p suppresses hepatocellular carcinoma chemoresistance by targeting YAP1 expression. EBioMedicine. 2018;35:142-54.
Ng K, Yeung O, Liu J, Li CX, Liu H, Liu XB, et al. Clinical significance and functional role of transmembrane protein 47 (TMEM47) in chemoresistance of hepatocellular carcinoma. Int J Oncol. 2020;57:956-66.
Royer B, Schmitt A, Nguyen T, Paillard MJ, Jary M, Demarchi M, et al. Exposure-response analysis of raltitrexed assessing liver toxicity. Brit J Clin Pharmaco. 2021;87:1327-37.
Batra A, Rigo R, Hannouf MB, Cheung WY. Real-world safety and efficacy of raltitrexed in patients with metastatic colorectal cancer. Clin Colorectal Canc. 2021;20:e75-e81.
El-Mesallamy HO, El Magdoub HM, Chapman JM, Hamdy NM, Schaalan MF, Hammad LN, Berger SH. Biomolecular study of human thymidylate synthase conformer-selective inhibitors: new chemotherapeutic approach. PloS One. 2018;13:e193810.
Chen Y, Wu J, Cheng K, Li ZP, Luo DY, Qiu M, et al. S-1 plus raltitrexed for refractory metastatic colorectal cancer: a phase II trial. Oncologist. 2019;24:591.
Cui W, Fan W, Zhang Q, Wen J, Huang Y, Yang J, et al. Comparison of two transarterial chemoembolization regimens in patients with unresectable hepatocellular carcinoma: raltitrexed plus oxaliplatin versus 5-fluorouracil plus oxaliplatin. Oncotarget. 2017;8:79165-74.
Fukui H, Saito H, Ueno Y, Uto H, Obara K, Sakaida I, et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015. J Gastroenterol. 2016;51:629-50.
Pinato DJ, Sharma R, Allara E, Yen C, Arizumi T, Kubota K, et al. The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma. J Hepatol. 2017;66:338-46.
Matsuo N, Uchida H, Sakaguchi H, Nishimine K, Nishimura Y, Hirohashi S, et al. Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma: study based on lipiodol accumulation patterns and histopathologic findings. Semin Oncol. 1997;24:S6-61.
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Canc. 2009;45:228-47.
Lee SW, Lee HL, Han NI, Kwon JH, Nam SW, Jang JW, et al. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-fluorouracil versus transarterial chemoembolization using doxorubicin for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective analysis. Ther Adv Med Oncol. 2017;9:615-26.
Yoo SH, Kwon JH, Nam SW, Lee JY, Kim YW, Shim DJ, et al. Transarterial infusion of epirubicin and cisplatin combined with systemic infusion of 5-flurouracil versus sorafenib for hepatocellular carcinoma with refractoriness of transarterial chemoembolization using doxorubicin. Cancer Control: J Moffitt Canc Cent. 2020;27:1148371107.
Teran-Saavedra NG, Sarabia-Sainz JA, Velázquez-Contreras EF, Ramos-Clamont Montfort G, Pedroza-Montero M, Vazquez-Moreno L. Albumin-albumin/lactosylated core-shell nanoparticles: therapy to treat hepatocellular carcinoma for controlled delivery of doxorubicin. Molecules. 2020;25:5432.
Nasr M, Nafee N, Saad H, Kazem A. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice. Eur J Pharm Biopharm. 2014;88:216-25.
Huang D, Ba Y, Xiong J, Xu N, Yan Z, Zhuang Z, et al. A multicentre randomised trial comparing weekly paclitaxel+S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer. Eur J Canc. 2013;49:2995-3002.
Hamano H, Ikeda Y, Goda M, Fukushima K, Kishi S, Chuma M, et al. Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity. Kidney Int. 2021;99:885-99.
Qi C, Gao H, Li S, Zong H, Hao H, Zhang L. A case-control study on the correlation between thymidylate synthase gene polymorphisms and raltitrexed treatment combined with transcatheter arterial chemoembolization in hepatocellular carcinoma treatment. Genet Test Mol Biomarkers. 2020;24:156-64.
Guo J, Zhang H, Gao S, Zhang P-J, Li X-T, Chen H, et al. Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis. World J Gastroenterol. 2017;23:1406.
Shao W, Li C, Tang J, Song J, Li Z, Sun J, et al. Efficacy and safety of raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Canc Manag Res. 2019;11:9863-9.
Zhao C, Fan L, Qi F, Ou S, Yu L, Yi X, et al. Raltitrexed plus oxaliplatin-based transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Anticancer Drugs. 2016;27:689-94.
Ren B, Wang W, Shen J, Li W, Ni C, Zhu X. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE alone for unresectable hepatocellular carcinoma: a propensity score matching study. J Cancer. 2019;10:1189-96.
Kong J, Li S, Fan H, Zhang L, Zhao H, Li S. Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma. Medicine (Baltimore). 2018;97: e11872.
Liao R, Zhang X, Li G, Qin K, Yan X. Comparison of transcatheter arterial chemoembolization with raltitrexed plus liposomal doxorubicin vs. tegafur plus pirarubicin for unresectable hepatocellular carcinoma. J Gastrointest Oncol. 2020;11:747-59.
Chu HH, Chun S, Kim JH, Kim PH, Gwon DI, Ko HK, Kim N. A prediction model for overall survival after transarterial chemoembolization for hepatocellular carcinoma invading the hepatic vein or inferior vena cava. Eur Radiol. 2020:11-26.
Liu L, Zhang Q, Geng J, Li S, Zhao S, Zhang X, et al. Comparison of radiofrequency ablation combined with sorafenib or sorafenib alone in patients with ECOG performance score 1: identifying optimal candidates. Ann Transl Med. 2020;8:583.
Chen C, Qiu H, Yao Y, Zhang Z, Ma C, Ma Y, et al. Comprehensive predictive factors for CalliSpheres® microspheres (CSM) drug-eluting bead-transarterial chemoembolization and conventional transarterial chemoembolization on treatment response and survival in hepatocellular carcinoma patients. Clin Res Hepatol Gastroenterol. 2020:101460.
Zhao S, Dou W, Fan Q, Hu J, Li H, Zhang X, et al. Identifying optimal candidates of transarterial chemoembolization (TACE) vs. sorafenib in patients with unresectable hepatocellular carcinoma. Ann Transl Med. 2020;8:587.